Literature DB >> 32749665

Long noncoding RNA DUXAP8 regulates proliferation and apoptosis of ovarian cancer cells via targeting miR-590-5p.

Qingyou Meng1, Zhongliang Li1, Jiaxue Pan1, Xiaorong Sun2.   

Abstract

The aim of this study is to investigate the effect of lncRNA DUXAP8 on proliferation and apoptosis of ovarian cancer cells, and to explore its potential mechanism. DUXAP8 interfering and overexpressing cell lines were constructed and the cell proliferation and apoptosis were tested. Hematoxylin-eosin, TdT-mediated dUTP nick end labeling, and immunohistochemistry were used to detect the effect of DUXAP8 on the ability of tumor formation. Quantitative real-time polymerase chain reaction and western blot were used to detect the mRNA and protein expression of miR-590-5p and YAP1, respectively. Dual luciferase assay was used to determine the target relationship between DUXAP8, miR-590-5p, and YAP1. DUXAP8 interference and miR-590-5p down-regulated cell lines were further constructed. Compared with normal ovarian cells, the expression of DUXAP8 in ovarian cancer cells was significantly increased, while the expression of miR-590-5p was decreased (p < 0.05). After DUXAP8 interference, cell proliferation and colony formation were decreased, and apoptosis was increased. The results of in vivo experiment are consistent with the in vitro experiments. The expression of miR-590-5p was up-regulated and the expression of YAP1 was decreased after DUXAP8 interference. Moreover, miR590-5p inhibitor can attenuate the effect of DUXAP8 interference on ovarian cancer cells. Taken together, lncRNA DUXAP8 can regulate the proliferation and apoptosis of ovarian cancer cells, and its mechanism may be related to the regulation of YAP1 gene by targeting miR-590-5p.

Entities:  

Keywords:  Apoptosis; Ovarian cancer; Proliferation; YAP1; lncRNA DUXAP8; miR-590-5p

Mesh:

Substances:

Year:  2020        PMID: 32749665     DOI: 10.1007/s13577-020-00398-8

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  4 in total

1.  Mechanism of lncRNA DUXAP8 in promoting proliferation of bladder cancer cells by regulating PTEN.

Authors:  M-G Lin; Y-K Hong; Y Zhang; B-B Lin; X-J He
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-06       Impact factor: 3.507

Review 2.  Ovarian cancer: an overview.

Authors:  Michelle A Roett; Patricia Evans
Journal:  Am Fam Physician       Date:  2009-09-15       Impact factor: 3.292

3.  Long non-coding RNA DUXAP8 regulates proliferation and invasion of esophageal squamous cell cancer.

Authors:  L-J Xu; X-J Yu; B Wei; H-X Hui; Y Sun; J Dai; X-F Chen
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-05       Impact factor: 3.507

4.  miR‑590‑5p inhibits tumor growth in malignant melanoma by suppressing YAP1 expression.

Authors:  Kuanhou Mou; Meiling Ding; Dan Han; Yan Zhou; Xin Mu; Wenli Liu; Lijuan Wang
Journal:  Oncol Rep       Date:  2018-08-07       Impact factor: 3.906

  4 in total
  4 in total

Review 1.  Functions of lncRNA DUXAP8 in non-small cell lung cancer.

Authors:  Cui Wu; Wu Song; Zhongnan Wang; Bingmei Wang
Journal:  Mol Biol Rep       Date:  2022-01-15       Impact factor: 2.316

Review 2.  The interplay between noncoding RNA and YAP/TAZ signaling in cancers: molecular functions and mechanisms.

Authors:  Yirao Zhang; Yang Wang; Hao Ji; Jie Ding; Keming Wang
Journal:  J Exp Clin Cancer Res       Date:  2022-06-14

3.  Long non-coding RNA DUXAP8 promotes tumorigenesis by regulating IGF1R via miR-9-3p in hepatocellular carcinoma.

Authors:  Qiang Guan; Bo Yuan; Xiaobin Zhang; Tinghai Yan; Jiangong Li; Wuzhong Xu
Journal:  Exp Ther Med       Date:  2021-05-12       Impact factor: 2.447

4.  LncRNA DUXAP8 as a prognostic biomarker for various cancers: A meta-analysis and bioinformatics analysis.

Authors:  Yongfeng Wang; Xianglai Jiang; Dongzhi Zhang; Yuanbin Zhao; Xiaoyong Han; Lihui Zhu; Jingyao Ren; Yubin Liu; Jiarong You; Haolan Wang; Hui Cai
Journal:  Front Genet       Date:  2022-08-15       Impact factor: 4.772

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.